Product
Astugenal
Aliases
AS2-1
2 clinical trials
1 indication
Indication
Brainstem GliomaClinical trial
A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem GliomaStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem GliomaStatus: Not yet recruiting, Estimated PCD: 2025-12-01